Abstract
In the CARD study (NCT02485691), cabazitaxel significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) vs abiraterone or enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer who had received docetaxel and progressed ≤ 12 months with the alternative androgen receptor-targeted agent (ARTA). Here we analyzed the morphology of CTC subtypes in a liquid biopsy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
